FREELINE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc – FRLN

NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ — Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of  Freeline Therapeutics Holdings plc (NasdaqCM: FRLN) to  Syncona Ltd.  Under the terms of the proposed transaction, shareholders of Freeline will receive $6.50 for each American Depositary Share (ADS) of Freeline that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit  https://www.ksfcounsel.com/cases/nasdaqcm-frln/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163

SOURCE Kahn Swick & Foti, LLC

Go to Source